Johnson & Johnson halts development of RSV vaccine in midst of late-stage clinical trials
The company was in late-stage clinical trials of a vaccine to prevent lower respiratory tract disease in adults over the age of 60 with RSV. The vaccine being tested was using an adenovirus vector platform, similar to the technology behind in its COVID-19 vaccine.